Skip to main content

Table 3 Anti-RBD levels: demographic factors (univariable analyses of factors associated with dose response)

From: Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study

 

Before propensity score matching

   

After propensity score matching

   

Characteristic

Response to dose-1 (%)

p-value

Response to dose-2 (%)

p-value

Response to dose-1 (%)

p-value

Response to dose-2 (%)

p-value

Male

59 (71.08)

0.198

78 (71.56)

0.295

32 (71.1)

0.365

46 (67.6)

0.759

Hypertension

38 (45.78)

0.194

53 (48.62)

0.252

29 (64.4)

0.430

38 (55.8)

0.419

Diabetes

35 (42.17)

0.898

49 (44.95)

0.040

12 (26.6)

0.108

25 (36.7)

0.023

Triple regimen (TMP)

27 (32.53)

0.000

52 (47.71)

0.000

21 (46.6)

0.000

41 (60.2)

0.003

Agea

1.02

0.018

0.979

0.079

0.99

0.985

0.96

0.028

Time since Txa

0.99

0.740

1.007

0.831

0.99

0.907

0.96

0.377

HBVb

13 (24.53)

0.605

17 (32.08)

0.036

5 (33.3)

0.201

6 (31.5)

0.254

  1. aOdds ratio
  2. bIn liver transplant patients only